These include in MEN1/ZES patients the management of gastric carcinoids (Type 2 carcinoids); controversies of the roles of imaging/tumor localization for gastrinomas/pNETs in the initial/follow-up management of MEN1/ZES patients; and the possible important prognostic value of type of MEN1 germline mutation present in MEN1/ZES patients. The gene discussed is MEN1; the disease is gastrin-producing neuroendocrine tumor.